Skip to content
BALCAO · SERVICES-MEDICAL LABORATORIES

Renalytix PLC RNLXY

6 fiscal years on record · USD · FY2023 reported · SEC filings only
$2.3M
▼ 32.7% YoY
$-33.5M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 2.3M
Revenue, FY2023 · full 6-year series below
Revenue $M Net income $M
FY2023 · Revenue 2.3 · Net income -33.5
-20M-40M
201820212023
Compound annual growth
+15.4%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2023 · Operating -1293.5%
-1000%-2000%
201820202023
ROE
FY2022 · ROE -242.8%
-200%-400%
201820202023
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2023 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -34.1
-20M-40M
201820202023

Total assetsUSD 8.0M
EquityUSD -7.9M
CashUSD 4.7M
Current ratio0.53×

Equity funds -99% of total assets.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
RNLXY, 6-year financial record
Metric 202320222021202020192018
Revenue $B0.00.00.00.00.0◌
Operating income $B−0.0−0.0−0.1−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.1−0.0−0.0−0.0
Income tax $B0.00.00.00.00.0◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B◌−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.31−0.55−0.67−0.49−0.17−0.99
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %—−242.8−88.7−80.9−80.5−494.7
Shares out B0.150.090.070.070.060.05

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 29 reconciliationsAUDITED

Reconciled in 6 of the 6 fiscal years we could check. 22 checks were skipped: the balance sheet is not tagged before 2018. 12 checks were skipped: revenue is not tagged before 2019. 11 checks were skipped: EPS is not tagged before 2018.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityServices-Medical Laboratories
Listed onOTC market
Incorporated inoutside the United States — SEC code X0
Fiscal year endsJune 30
SEC categoryemerging growth company
Data on record since2018

Share this section

Download image